Biotechnology

Dynavax Tech

Sanofi Completes Acquisition of Denali Pharmaceuticals

Sanofi Acquires Denali to Strengthen Adult Vaccine Market

Dynavax Tech released FY2025 9 Months Earnings on November 5 After-Market EST, with actual revenue of USD 258.48 M and EPS of USD -0.4157

Dynavax Tech released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 94.88 M (forecast USD 94 M), actual EPS USD 0.2063 (forecast USD 0.1166)

Denali Pharmaceuticals Reports Q3 2025 Earnings and Announces Stock Repurchase Plan

Dynavax Tech to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 94 M, EPS USD 0.1166

Denavi Pharmaceutical Q2 Earnings Beat Expectations

Dynavax Tech released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 95.44 M (forecast USD 86.66 M), actual EPS USD 0.14 (forecast USD 0.115)

Dynavax Tech released FY2025 Semi-Annual earnings on August 7 After-Market (EST), actual revenue USD 163.61 M, actual EPS USD -0.6338

Dynavax Reports Q2 2025 HEPLISAV-B Revenue Record High

Denavi Pharmaceutical Reports Q2 Earnings

Dynavax Tech to Release FY2025 Q2 Earnings on August 7 After-Market EST, Forecast Revenue USD 86.66 M, EPS USD 0.115

Denave Pharmaceuticals Holds Annual Shareholders Meeting to Elect New Directors

Denawee Pharmaceutical Holds Annual Shareholders' Meeting

Deep Track Capital Sends Letter to Denavi Pharmaceutical Shareholders for Board Changes

Denawi Pharma Urges Shareholders to Support Director Nominations

Denavir Pharmaceutical Successfully Implements Strategy to Create Value for Shareholders

Glass Lewis Advises Shareholders to Support Two Director Nominees for Denali Therapeutics

Denali Therapeutics to Speak at William Blair Growth Stock Conference

DanaVie Pharmaceuticals Appoints New Vice President and Chief Accounting Officer

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

DVAX

VXRT

SBIO

ARKG

IBBQ

Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID-19 trial. The trial is fully enrolled with 5,400 participants, and results are expected in early 2027. The company reported a strong financial position with $61M cash, ensuring funding into Q2 2027. Actions taken to extend runway include restoring BARDA funding and a strategic partnership with Dynavax.

TradingView

Vaxart

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

VG Health

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Pharma

Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027

Dynavox Group Highlights Mission in 2025 Annual and Sustainability Report

Tip Ranks

Dynavox Group Highlights Mission in 2025 Annual and Sustainability Report

LEXX

Resverlogix Corp. Provides Bi-Weekly MCTO Status Update | RVXCF Stock News

StockTitan

Lexaria Bioscience

Lexicon Pharma

Resverlogix Corp. Provides Bi-Weekly MCTO Status Update | RVXCF Stock News

Dynavox Group AB announced that CFO Linda Tybring will step down by January 31, 2027, to ensure a smooth transition and assist in recruiting her successor. The company has begun an immediate search for a new CFO, highlighting Tybring's significant contributions to its growth, including its 2021 carve-out from Tobii and international acquisitions. The transition aims to maintain operational continuity during ongoing expansion. The current analyst rating for Dynavox Group stock is a Hold with a price target of SEK125.00.

Dynavox Group CFO to Step Down in Planned Transition by January 2027

BioVaxys Extends Financial Filing Delay Under Management Cease Trade Order

Art Tech Acquisition - Unit

BioVaxys Extends Financial Filing Delay Under Management Cease Trade Order

PCVX

BioVaxys Technology Corp. has provided a bi-weekly update regarding its management cease trade order (MCTO) issued by the British Columbia Securities Commission. The company is working to complete its audited annual financial statements, which were due by February 28, 2026, and anticipates filing them by April 28, 2026. Due to this delay, the company will also postpone its interim financial statements due by April 1, 2026. The MCTO restricts trading for the CEO and CFO but allows public trading of the company's shares.

The newswire.ca

Vaxcyte

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

A recent study suggests that the shingles vaccine may reduce the risk of developing Alzheimer's by 20%. Researchers have identified eight existing drugs, including Viagra and riluzole, that could potentially help fight dementia. The findings, published in Alzheimer's Research & Therapy, highlight the urgent need for further investigation into these drugs as dementia rates rise globally. The study emphasizes the importance of the shingles vaccine, which has shown significant protective effects against dementia in a large population study in Wales.

- A recent study suggests that the shingles vaccine may reduce the risk of developing Alzheimer's by up to 20%, based on data from hundreds of thousands of individuals.  
- Researchers are advocating for further investigation of existing drugs, including both the shingles vaccine and Viagra, for their potential benefits in combating dementia.  
- The analysis highlights the shingles vaccine's strong evidence as a preventive measure against dementia, with the new Shingrix vaccine possibly offering even greater protective effects.

Dow Jones

Viatris

Sanofi

Direxion Daily Biotech Top 5 Bull 2X ETF

Pfizer

Teva Pharmaceutical Industries

These 8 drugs could help fight dementia - and they're already on the market

BioVaxys Technology Corp. announced it could not file its annual financial statements by the February 28, 2026 deadline due to delays in auditing caused by changes in accounting systems. Consequently, the company applied for a management cease trade order (MCTO), which was granted on March 3, 2026, prohibiting trading by its CEO and CFO. The company expects to complete the annual filings by April 28, 2026, and will comply with alternative information guidelines during this period.

BioVaxys Announces Application for Management Cease Trade Order

A study published in the Journal of the American Medical Association reveals that hepatitis B vaccination rates among U.S. newborns peaked at 83.5% in February 2023 but fell to 73.2% by August. The CDC recently removed the hepatitis B vaccine from its universal childhood immunization schedule, although it still recommends it for infants born to mothers with unknown HPV status. This change has led to a lawsuit from several Democratic-led states against federal health officials, claiming it will negatively impact children's health and state resources.

Thehill

Merck

Newborn Hepatitis B vaccine rates peaked in 2023, then slipped: Research

Principal Financial Group Inc. reduced its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 12.9% in Q3, now holding 482,247 shares valued at $4.79 million. Other hedge funds have also adjusted their positions. The stock opened at $15.50, with a market cap of $1.82 billion. Analysts have mixed ratings on DVAX, with a consensus rating of "Hold" and a price target of $24.33. Dynavax focuses on developing vaccines and immunotherapies, including its FDA-approved hepatitis B vaccine, HEPLISAV-B.

Market Beat

Dynavax Technologies Corporation $DVAX Stock Position Lowered by Principal Financial Group Inc.

Dynavax Tech(DVAX.US)

Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027

Dynavox Group Highlights Mission in 2025 Annual and Sustainability Report

Resverlogix Corp. Provides Bi-Weekly MCTO Status Update | RVXCF Stock News

Dynavox Group CFO to Step Down in Planned Transition by January 2027

BioVaxys Extends Financial Filing Delay Under Management Cease Trade Order

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

These 8 drugs could help fight dementia - and they're already on the market

BioVaxys Announces Application for Management Cease Trade Order

Newborn Hepatitis B vaccine rates peaked in 2023, then slipped: Research

Dynavax Technologies Corporation $DVAX Stock Position Lowered by Principal Financial Group Inc.